SG11201907211TA - Anti-pd-l1 antibody treatment of bladder cancer - Google Patents

Anti-pd-l1 antibody treatment of bladder cancer

Info

Publication number
SG11201907211TA
SG11201907211TA SG11201907211TA SG11201907211TA SG11201907211TA SG 11201907211T A SG11201907211T A SG 11201907211TA SG 11201907211T A SG11201907211T A SG 11201907211TA SG 11201907211T A SG11201907211T A SG 11201907211TA SG 11201907211T A SG11201907211T A SG 11201907211TA
Authority
SG
Singapore
Prior art keywords
medimmune
llc
gaithersburg
way
bladder cancer
Prior art date
Application number
SG11201907211TA
Other languages
English (en)
Inventor
John Kurland
John Blake-Haskins
Magdalena Zajac
Marlon Rebelatto
Ashok Gupta
Tony Ho
Jill Walker
Xiaoping Jin
Shannon Morris
Robert Iannone
Li Shi
Mohammed Dar
yong Ben
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of SG11201907211TA publication Critical patent/SG11201907211TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201907211TA 2017-02-16 2018-02-16 Anti-pd-l1 antibody treatment of bladder cancer SG11201907211TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762459700P 2017-02-16 2017-02-16
PCT/US2018/018513 WO2018152415A1 (en) 2017-02-16 2018-02-16 Anti-pd-l1 antibody treatment of bladder cancer

Publications (1)

Publication Number Publication Date
SG11201907211TA true SG11201907211TA (en) 2019-09-27

Family

ID=63169615

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907211TA SG11201907211TA (en) 2017-02-16 2018-02-16 Anti-pd-l1 antibody treatment of bladder cancer

Country Status (12)

Country Link
US (2) US20190359715A1 (https=)
EP (1) EP3582805A4 (https=)
JP (2) JP2020507596A (https=)
KR (3) KR20230145547A (https=)
CN (2) CN110290803A (https=)
AU (2) AU2018221822A1 (https=)
CA (1) CA3052652A1 (https=)
EA (1) EA201991870A1 (https=)
IL (3) IL302777A (https=)
MA (1) MA47509A (https=)
SG (1) SG11201907211TA (https=)
WO (1) WO2018152415A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3142751T3 (pl) * 2014-05-13 2019-12-31 Medimmune Limited Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca
KR20230145547A (ko) * 2017-02-16 2023-10-17 메디뮨 엘엘씨 방광암의 항-pd-l1 항체 치료
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
EP4153783A1 (en) * 2020-05-21 2023-03-29 Astrazeneca AB Tumor mutational burden associated with sensitivity to immunotherapy in locally advanced or metastatic urothelial carcinoma
US20250388678A1 (en) * 2024-06-25 2025-12-25 Astrazeneca Ab Methods, Combinations, and Uses for the Treatment of Muscle Invasive Bladder Cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947261B2 (en) * 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
PL3142751T3 (pl) * 2014-05-13 2019-12-31 Medimmune Limited Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca
RU2714233C2 (ru) * 2015-02-26 2020-02-13 Мерк Патент Гмбх Ингибиторы pd-1 / pd-l1 для лечения рака
ES2789500T5 (es) * 2015-05-29 2023-09-20 Hoffmann La Roche Procedimientos terapéuticos y de diagnóstico para el cáncer
US20180364240A1 (en) * 2015-12-10 2018-12-20 Medimmune, Llc Methods for treatment and selection of patients responsive to immune mediated cancer therapy
WO2017189433A1 (en) * 2016-04-25 2017-11-02 Medimmune, Llc Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies
KR20230145547A (ko) * 2017-02-16 2023-10-17 메디뮨 엘엘씨 방광암의 항-pd-l1 항체 치료

Also Published As

Publication number Publication date
WO2018152415A1 (en) 2018-08-23
US20220332828A1 (en) 2022-10-20
JP2020507596A (ja) 2020-03-12
US20190359715A1 (en) 2019-11-28
JP2024038034A (ja) 2024-03-19
EP3582805A1 (en) 2019-12-25
CA3052652A1 (en) 2018-08-23
CN118001389A (zh) 2024-05-10
EP3582805A4 (en) 2021-03-10
IL268460A (en) 2019-09-26
KR20250025517A (ko) 2025-02-21
CN110290803A (zh) 2019-09-27
KR20230145547A (ko) 2023-10-17
EA201991870A1 (ru) 2020-02-12
MA47509A (fr) 2019-12-25
AU2025201227A1 (en) 2025-03-13
AU2018221822A1 (en) 2019-09-26
IL320916A (en) 2025-07-01
KR20190117014A (ko) 2019-10-15
IL302777A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
SG11201907211TA (en) Anti-pd-l1 antibody treatment of bladder cancer
SG11201811432WA (en) Rna for cancer therapy
SG11201804839WA (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
SG11201803956UA (en) Anti-dr5 antibodies and methods of use thereof
SG11201809089QA (en) Bispecific binding proteins and uses thereof
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201909572QA (en) Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
SG11201900677SA (en) Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
SG11201907891XA (en) Combination therapy for the treatment or prevention of tumours
SG11201808242UA (en) Methods for inhibiting angiogenesis in a subject in need thereof
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201900344YA (en) Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
SG11201810883TA (en) Combination therapy
SG11201806340YA (en) Zika virus vaccine
SG11201901961SA (en) Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
SG11201806251WA (en) Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
SG11201809764XA (en) Humanized anti-il-1r3 antibodies
SG11201811292RA (en) Compositions and methods for the depletion of cells
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201808314QA (en) Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
SG11201900745VA (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
SG11201907207UA (en) Pharmaceutical combinations comprising an anti-ly75 antibody
SG11201806419RA (en) Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates